Abstract:Trophoblast cell surface antigen 2 (Trop2) is considered as a potential therapeutic target because its over-expression in tumors is found to be associated with poor prognosis of patients with different cancers. Trop2-directed antibody-drug conjugates have been approved for the treatment of solid tumors, however, the expression of Trop2 in a broad range of epithelial tissues, even in low expression, would limit their clinical benefits. The present work generated a novel Trop2/CD3 bispecific antibody with its binding affinity towards Trop2 being well-modulated to mitigate the chance of on-target off-tumor effect. By linking a humanized anti-Trop2 monoclonal antibody with a CD3-binding scFv, a Trop2/CD3 bispecific antibody was produced. In order to adjust the bispecific antibody's affinity to the tumor target, ProABC-2 was used for in-silico paratope prediction (Ambrosetti F et al., 2020). A complementarity-determining residue (CDR) variant was produced and its binding to Trop2 antigen was analyzed using biolayer interferometry. The binding of both wild type (WT) and variant antibodies to Trop2-positive cancer cells, the activation of T cells upon target engagement and the redirection of T cell-mediated killing on cancer cells expressing high level of Trop2 were examined. The binding affinity of CDR variant to Trop2-expressing tumor cells was significantly reduced, which led to a slower induction of cytokines and T-cell proliferation, less acute T-cell activation, and a milder cytotoxic effect. This allowed the bispecific antibody to have a higher level of safety by restricting the cytotoxicity only to cancer cells that expressed high level of Trop2. Our novel Trop2/CD3 bispecific antibody not only showed potent anti-tumor activity, but also demonstrated a lower risk of on-target off-tumor toxicity. Monkey toxicity and other IND-enabling studies are beginning to further bring the drug candidate into clinical trial. Table showing EC50 values of Trop2/CD3 bispecific WT and CDR variant antibodies in different assays WT CDR variant Binding affinity (M) Trop2 4.62E-11 2.14E-10 Cytotoxicity (M) AsPC1 (low Trop2 level) 1.24E-11 No killing effect SW480 (medium Trop2 level) 1.25E-12 2.25E-11 NCI-H596 (high Trop2 level) 5.65E-12 5.89E-10 Receptor occupancy (%) Trop2 0.65 2.75 CD3 0.08 5.83 Cytokine induction (M) IL-2 4.82E-11 5.42E-11 IFNγ 6.46E-13 2.59E-11 T cell activation (M) CD25+ marker 2.02E-12 2.39E-10 CD69+ marker 3.81E-13 7.40E-11 T cell proliferation (M) Ki-67 marker 3.54E-12 8.80E-11 Citation Format: Chui Yee O, Po Yee Wong, Kronos Chow, Kwan Wa Wong, Dennis Wong, John Moon Luk, Kwong Fai Wong. Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3212.

Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2

Targeting Trop2 in solid tumors: a look into structures and novel epitopes

Trop2-targeted therapy in breast cancer

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

Targeting Trop-2 in Cancer: Recent Research Progress and Clinical Application

Recent Advances in Trophoblast Cell-Surface Antigen 2 Targeted Therapy for Solid Tumors

Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.

Trophoblast Cell-Surface Antigen 2 is a Biomarker and Potential Therapeutic Target in Human Colon Cancer.

Abstract 3212: Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunotherapy for advanced gastrointestinal cancer treatment

A Novel Human Fab Antibody for Trop2 Inhibits Breast Cancer Growth in Vitro and in Vivo

An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers.

TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis

Design and synthesis of novel site-specific antibody-drug conjugates that target TROP2

Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth

Trop2-targeted therapies in solid tumors: advances and future directions

Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2

Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic properties

Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors

Abstract PR-04: A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook